| Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. | |
| | |
MedLine Citation:
|
PMID: 20630573 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To investigate the combined effect of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) and the protease inhibitor ritonavir on renal cancer cells. METHODS: Renal cancer cells (769P, 786O, A498, ACHN, Caki-1) and renal proximal tubule epithelial cells were treated with SAHA (0-5 μM) with or without ritonavir (0-50 μM). Cell viability, clonogenecity, and changes in cell cycle were evaluated. The expression of acetylated histone, retinoblastoma protein (Rb), phosphorylated Rb, histone deacetylases, X-linked inhibitor of apoptosis, survivin, and active caspase 3 was assessed using Western blot analysis. RESULTS: SAHA induced histone acetylation and Rb dephosphorylation and inhibited cell growth in a time- and dose-dependent manner. SAHA and ritonavir combined inhibited cell proliferation effectively and promoted histone acetylation and Rb dephosphorylation but only slightly affected renal proximal tubule epithelial cell survival. The combination induced the accumulation of the sub-G(1) fraction, decreased the expression of X-linked inhibitor of apoptosis and survivin, and increased active caspase 3, thus inducing apoptosis. It also inhibited the expression of histone deacetylases. CONCLUSIONS: Combination therapy using SAHA and ritonavir inhibited the proliferation of renal cancer cells effectively, perhaps by inhibiting both histone deacetylase function and expression. It might be a useful new regimen for treating renal cancer. |
| | |
Authors:
|
Akinori Sato; Takako Asano; Akio Horiguchi; Keiichi Ito; Makoto Sumitomo; Tomohiko Asano |
Related Documents
:
|
3078963 - Elevated expression of c-myc and n-myc produces distinct changes in nuclear fine struct... 15728493 - The ig kappa 3' enhancer is activated by gradients of chromatin accessibility and prote... 20492683 - Inhibition of nuclear factor-kappa b differentially affects thyroid cancer cell growth,... |
Publication Detail:
|
Type: Journal Article Date: 2010-07-13 |
Journal Detail:
|
Title: Urology Volume: 76 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-13 Completed Date: 2010-10-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: United States |
Other Details:
|
Languages: eng Pagination: 764.e7-13 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan. zenpaku@ndmc.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage* Drug Screening Assays, Antitumor Drug Therapy, Combination HIV Protease Inhibitors / administration & dosage* Hydroxamic Acids / administration & dosage* Kidney Neoplasms / drug therapy*, pathology Ritonavir / administration & dosage* Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/HIV Protease Inhibitors; 0/Hydroxamic Acids; 0/Ritonavir; 149647-78-9/vorinostat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: From a molecular biological viewpoint, does endothelin type A receptor antagonist therapy reduce dia...
Next Document: Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk.